Theranexus SA
ALTHX
Company Profile
Business description
Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company’s therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson’s disease, THN201 for the treatment of neurocognitive disorders in Alzheimer’s disease and THN101 for neuropathic pain.
Contact
60 avenue Rockefeller
Pepiniere Laennec
Lyon69008
FRASector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
10
Stocks News & Analysis
stocks
AI stocks post big gains in Q3. These are the winners and losers
Alphabet and Teradyne post big gains, while Salesforce and Adobe were down in the quarter.
stocks
12 picks for an income portfolio - Q3 2025 update
Fifteen months in and passive income growth has exceeded my target.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,253.60 | 25.70 | -0.28% |
| CAC 40 | 8,001.28 | 29.50 | 0.37% |
| DAX 40 | 24,433.08 | 54.79 | 0.22% |
| Dow JONES (US) | 46,694.97 | 63.31 | -0.14% |
| FTSE 100 | 9,490.21 | 11.07 | 0.12% |
| HKSE | 26,957.77 | 183.15 | -0.67% |
| NASDAQ | 22,941.67 | 161.16 | 0.71% |
| Nikkei 225 | 47,950.88 | 6.12 | 0.01% |
| NZX 50 Index | 13,531.29 | 42.05 | 0.31% |
| S&P 500 | 6,740.28 | 24.49 | 0.36% |
| S&P/ASX 200 | 8,956.80 | 19.10 | -0.21% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |